Recro Pharma Inc (NASDAQ:REPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “
Several other brokerages have also recently issued reports on REPH. Piper Jaffray Companies initiated coverage on shares of Recro Pharma in a research report on Monday, December 19th. They set an “overweight” rating and a $12.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $19.00 price target on shares of Recro Pharma in a research report on Tuesday, November 29th. Finally, Roth Capital set a $24.00 price target on shares of Recro Pharma and gave the company a “buy” rating in a research report on Monday, November 28th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $18.11.
Recro Pharma (NASDAQ:REPH) opened at 7.97 on Tuesday. Recro Pharma has a 52-week low of $5.59 and a 52-week high of $12.50. The firm’s 50 day moving average is $7.79 and its 200 day moving average is $7.95. The company’s market cap is $151.83 million.
Your IP Address:
In other Recro Pharma news, major shareholder Scp Vitalife Partners Ii Lp sold 44,977 shares of the company’s stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $8.00, for a total value of $359,816.00. Following the sale, the insider now owns 2,276,571 shares in the company, valued at $18,212,568. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Scp Vitalife Partners (Israel) sold 4,030 shares of the company’s stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $7.89, for a total transaction of $31,796.70. Following the completion of the sale, the insider now owns 772,714 shares in the company, valued at approximately $6,096,713.46. The disclosure for this sale can be found here. Insiders have sold 58,990 shares of company stock worth $467,384 in the last quarter. 39.30% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP acquired a new stake in shares of Recro Pharma during the fourth quarter worth $118,000. Acadian Asset Management LLC acquired a new stake in shares of Recro Pharma during the third quarter worth $140,000. Wells Fargo & Company MN boosted its stake in shares of Recro Pharma by 56.0% in the third quarter. Wells Fargo & Company MN now owns 31,200 shares of the specialty pharmaceutical company’s stock worth $276,000 after buying an additional 11,200 shares during the period. Numeric Investors LLC acquired a new stake in shares of Recro Pharma during the fourth quarter worth $556,000. Finally, Granite Point Capital Management L.P. acquired a new stake in shares of Recro Pharma during the third quarter worth $636,000. Institutional investors and hedge funds own 53.23% of the company’s stock.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2024696/zacks-investment-research-downgrades-recro-pharma-inc-reph-to-hold.html
Receive News & Ratings for Recro Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.